EVOMMUNE INC (EVMN) Forecast, Price Target & Analyst Ratings

Q: What do analysts expect the price target to be for EVOMMUNE INC (EVMN)?

15 analysts have analysed EVMN and the average price target is 52.02 USD. This implies a price increase of 103.92% is expected in the next year compared to the current price of 25.51.

NYSE:EVMN • US30054Y1073

25.51 USD

-3.14 (-10.96%)

At close: Apr 10, 2026

25.51 USD

0 (0%)

After Hours: 4/10/2026, 8:19:45 PM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for EVOMMUNE INC (EVMN).

Consensus Price Target

Price Target

$52.02

+ 103.92% Upside

→ Price target details

Next Earnings Forecast

Earnings Estimate

Release Date: N/A
Period: Q1 / 2026
EPS Estimate: -$0.74
Revenue Estimate

→ Full earnings forecast details

ChartMill Buy Consensus

Rating

86.67%

Weighted Analyst Rating Score

→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target

$52.02

Upside

+ 103.92%

From current price of $25.51 to mean target of $52.02, Based on 15 analyst forecasts

Low

$48.48

Median

$51.00

High

$57.75

Price Target Revisions

1 Month

-5.56%

3 Months

30.77%

Price Target Summary

15 Wall Street analysts provided a forecast for the next 12 months for EVMN. The average price target is 52.02 USD. This implies a price increase of 103.92% is expected in the next year compared to the current price of 25.51.

The average price target has been revised upward by 30.77% in the past 3 months.

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus

86.67%

EVMN was analyzed by 15 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about EVMN.

In the previous month the buy percentage consensus was at a similar level.

EVMN was analyzed by 15 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.

→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Date	Firm	Action	From → To
2026-04-10	RBC Capital	Reiterate	Outperform -> Outperform
2026-03-18	Clear Street	Initiate	Buy
2026-03-18	HC Wainwright & Co.	Maintains	Buy -> Buy
2026-02-10	HC Wainwright & Co.	Maintains	Buy -> Buy
2026-01-22	Oppenheimer	Initiate	Outperform
2026-01-08	Raymond James	Initiate	Strong Buy
2026-01-06	HC Wainwright & Co.	Initiate	Buy
2025-12-01	Leerink Partners	Initiate	Outperform
2025-12-01	Cantor Fitzgerald	Initiate	Overweight
2025-12-01	William Blair	Initiate	Outperform
2025-12-01	Evercore ISI Group	Initiate	Outperform
2025-12-01	Morgan Stanley	Initiate	Overweight

Next Earnings Forecast Details

Next Earnings Details

Release Date: N/A
Period: Q1 / 2026
EPS Estimate: -$0.74
Revenue Estimate
Revenue Q2Q: N/A
EPS Q2Q: N/A
Number of Analysts: 10

Next Earnings Revisions

Revenue (1 Month)

N/A

Revenue (3 Months)

N/A

EPS (1 Month)

N/A

EPS (3 Months)

N/A

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2025 - 2028

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

	2023	2024	2025	2026	2027	2028
Revenue YoY % growth	5M	7M 40.00%	13.26M 89.43%	-100.00%
EBITDA YoY % growth	-36.85M	-68.726M -86.50%	-79.653M -15.90%	-113.671M -42.71%	-142.283M -25.17%	N/A
EBIT YoY % growth	-37.85M	-70.013M -84.97%	-76.055M -8.63%	-112.88M -48.42%	-145.692M -29.07%	-178.585M -22.58%
Operating Margin	-757.00%	-1,000.19%	-573.56%	N/A	N/A	N/A
EPS YoY % growth	N/A	N/A	-4.21	-2.82 33.00%	-3.26 -15.40%	N/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

	Q1 / 26	Q2 / 26	Q3 / 26	Q4 / 26	Q1 / 27	Q2 / 27	Q3 / 27	Q4 / 27	Q1 / 28	Q2 / 28	Q3 / 28	Q4 / 28
EPS Q2Q % growth	-0.74	-0.69	-0.71	-0.79 45.08%	-0.81 -8.64%	-0.85 -23.09%	-0.87 -22.30%	-0.87 -10.39%	-0.87 -7.59%	-0.87 -2.41%	-0.94 -8.24%	-0.94 -8.24%
Revenue Q2Q % growth		-100.00%			N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EBITDA Q2Q % growth	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EBIT Q2Q % growth	-27.687M	-28.438M 25.22%	-26.445M	-32.36M -31.60%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year

-12.77%

EPS Next 5 Year

N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year

-25.99%

Revenue Next 5 Year

-18.92%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year

-26.67%

EBIT Next 5 Year

N/A

→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

EVOMMUNE INC / EVMN Forecast FAQ

What do analysts expect the price target to be for EVOMMUNE INC (EVMN)?

15 analysts have analysed EVMN and the average price target is 52.02 USD. This implies a price increase of 103.92% is expected in the next year compared to the current price of 25.51.

What are the consensus estimates for EVOMMUNE INC (EVMN) next earnings?

The consensus EPS estimate for the next earnings of EVOMMUNE INC (EVMN) is -0.74 USD and the consensus revenue estimate is 0 USD.

Can you provide the analyst count for EVOMMUNE INC stock?

The number of analysts covering EVOMMUNE INC (EVMN) is 15.

Analyst forecast overview

Forecast Snapshot